ChemExpress invites new and old customers to attend 2020 API China Qingdao (S4F13)
2020-06-05 10:22:34
Page View：666
Back
API China (Qingdao)
The 23th CHINA-PHARM & The 84th API China
Exhibition time: 9-11 June, 2020
Venue: Qingdao Cosmopolitan Exposition
Address: No.3399 Sansha Road the West Coast New Area , Qingdao Shandong Province, China
Booth No.：S4F13
ChemExpress, founded in 2006, is a high-tech enterprise located in Zhangjiang Hi-Tech Park. We are mainly engaged in the development, production, sales of novel compounds, API, and advanced intermediates for generic drugs. As a fast-growing CRO & CDMO company, we have established the R&D platform centering on featured APIs to provide customers with full services ranging from research, manufacture to registration.
We have completed the process development of more than 100 APIs and intermediates in the field of anti-tumor, anti-viral, anti-diabetic, and cardiovascular, such as key intermediates of Favipiravir, Baloxavir Marboxil, Rucaparib, and Rucaparib.
Fampranavir
An RdRP inhibitor is a broad-spectrum anti-influenza virus drug that is currently undergoing clinical studies of COVID-19.
Baloxavir Marboxil
The drug is a first-in-class cap-dependent endonuclease inhibitor of the influenza virus. Which blocks viral reverse transcription by inhibiting "CAP-snatching" endonuclease, effectively kills the influenza virus in one day with a single dose.
Ribociclib
It is a selective inhibitor of cyclin-dependent kinases for the treatment of HR+/HER2- advanced or metastatic breast cancer.
Rucaparib
It is a PARP inhibitor, the first PARP drug to receive breakthrough drug approval,used for the treatment of fallopian tube cancer, ovarian cancer, peritoneal cancer.
We focus on the development of featured APIs. Based on our strong process chemistry R&D platform, we have served global pharmaceutical enterprises and research institutions with pharmaceutical intermediates and APIs on a large scale accompanied by technical services.
